Search results
Novel T-cell engager, CDH17 X CD3 cabotamig (ARB202) continues to explore dosing in patients with...
Casper Star-Tribune· 2 days agoArbele, a clinical-stage biotechnology company focused on the development of novel immunotherapies targeted for advanced gastrointestinal cancers, today announced the positive recommendation ...
Small Business - Cordele Dispatch | Cordele Dispatch
Cordele Dispatch· 4 days agoNew York, USA, April 24, 2024 (GLOBE NEWSWIRE) -- HDAC Inhibitor Market to Observe Stunning Growth During the Study Period (2020–2034) | DelveInsight According to DelveInsight’s analysis, the growth of the HDAC inhibitors market is expected